Oncology Corporate Profile
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|VB-111||anti angiogenic agent||Glioblastoma Multiforme (GBM)||III|
|VB-111||anti angiogenic agent||Ovarian cancer||II|
|VB-111||anti angiogenic agent||Thyroid cancer||II|
|VB-111||anti angiogenic agent||Various cancer types||I|
View additional information on product candidates here »
4/3/2017 11:01 am
4/3/2017 11:00 am
[GlobeNewswire] - Phase 2 Study of VB-201 Shows Reduction in Liver Enzymes. Data Presented Today at H.C. Wainwright Annual NASH Investor Conference.
3/30/2017 05:00 pm
3/28/2017 11:00 am
[GlobeNewswire] - TEL AVIV, Israel, March 28, 2017-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...